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Oxazaphosphorines belong to a group of alky-
lating agents with a broad spectrum of antitumor
activity in man. Cyclophosphamide (CP) is a key
substance, that possesses high activity against both
many experimental tumors and in clinical condi-
tions; however, oxazaphosphorines group contains
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Abstract: The oxazaphosphorines alkylating agents (cyclophosphamide; CP and ifosfamide; IF) are often used
in common clinical practice. However, treatment with CP/IF is burdened with the risk of many adverse drug
reactions, especially including hemorrhagic cystitis (HC) that is associated with bladder overactivity symptoms
(OAB). The HC pathophysiology is still not fully displayed; it seems that autonomic nervous system (ANS)
functional abnormalities play important role in this disturbance. The aim of our study was to reveal the poten-
tial ANS differences in rat experimental HC model, evoked by CP and IF by an indirect ANS assessment - heart
rate variability (HRV) study. We carried out our experimental research in three essential groups: control group
(group 1), cyclophosphamide-induced HC (CP-HC; group 2) one and ifosfamide-induced HC (IF-HC; group 3)
one. CP was i.p. administrated four times in dose of 75 mg/kg body weight while IF-treated rats received i.p.
five drug doses; 50 mg/kg body weight. Control rats were administrated i.p. vehicle in appropriate volumes as
CP/IF treated animals. HRV studies were performed the next day after the last oxazaphosphorines dose.
Standard time- and spectral (frequency) domain parameters were estimated. We confirmed the HC development
after both CP/IF in macroscopic assessment and bladder wet weight measurement; however, it was more aggra-
vated in CP-HC group. Moreover, we demonstrated HRV disturbances, suggesting ANS impairment after both
studied oxazaphosphorines, however, consistent with the findings mentioned above, the autonomic dysfunction
was more emphasized after CP. CP treatment was also associated with changes of non-normalized HRV spec-
tral components percentage distribution - a marked very low frequency - VLF [%] increase together with low
frequency -LF [%] and high frequency - HF [%] decrease were observed. Taking into consideration the next
findings, demonstrating the lack of both normalized power spectral components (nLF and nHF) values, the VLF
percentage change seems to be of special meaning. IF produced smaller autonomic disturbances, and gentler
bladders histological abnormalities comparing to CP. However, similar to CP, VLF [%] relative augmentation
together with LF [%] and HF [%] drop accompanied the global ANS activity decrease. Additionally, in the case
of IF treatment, a slight trend of nLF increase with nHF decrease was noted, suggesting the possible function-
al rearrangement between sympathetic (nLF) and parasympathetic (nHF) tension. It seems possible that the
vagal withdrawal and - as a consequence - sympathetic overactivity, reflected by VLF [%] enlargement and HF
and LF [%] diminishing (as well as LF and HF values decrease), may be an evidence of impaired anti-inflam-
matory cholinergic pathway, aggravating bladder inflammatory lesions. To sum up, our study showed ANS
impairment in both CP- and IF-evoked experimental HC that was reflected in HRV recordings. HRV study,
thus, may be considered to be a diagnostic tool for CP/IF treated patients, estimating autonomic abnormalities,
associated with the HC development risk and its clinical course. 
Keywords: oxazaphosphorines, cyclophosphamide, ifosfamide, hemorrhagic cystitis, autonomic nervous sys-
tem, heart rate variability (HRV) 
Abbreviations: ANS - autonomic nervous system, CP ñ cyclophosphamide, CP-HC ñ cyclophosphamide-
induced HC, HC ñ hemorrhagic cystitis, HF ñ high frequency (a HRV spectrum component), HRV ñ heart rate
variability, IF ñ ifosfamide, IF-HC ñ ifosfamide-induced HC, LF ñ low frequency (a HRV spectrum compo-
nent), nHF ñ normalized HF, nLF ñ normalized LF, OAB ñ overactive bladder, RMSSD ñ the square root of
the mean squared difference of successive normal-normal (R-R) intervals, SDNN ñ the standard deviation of
all normal-normal (R-R) intervals, VLF ñ very low frequency (a HRV spectrum component).
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also other agents: ifosfamide, trofosfamide, sufos-
famide and mafosfamide (1, 2). 
Cyclophosphamide is one of the most fre-
quently used oxazaphosphorine agent and although
effective alone in susceptible malignancies, is more
frequently used concurrently or sequentially with
other antineoplastic drugs. The following malignan-
cies are often susceptible to CP treatment:
Hodgkinís disease, lymphocytic lymphoma (nodular
or diffuse), mixed-cell type lymphoma, histiocytic
lymphoma, Burkittís lymphoma, multiple myeloma,
chronic lymphocytic leukemia, chronic granulocytic
leukemia (but it is usually ineffective in acute blas-
tic crisis), acute myelogenous and monocytic
leukemia, acute lymphoblastic (stem-cell) leukemia
in children (when given during remission is effec-
tive in prolonging its duration). Moreover, CP is
used in management of breast cancer, mycosis fun-
goides, neuroblastoma, ovarian adenocarcinoma,
and retinoblastoma. CP is also used in non-malig-
nant diseases, mostly in biopsy proven ìminimal
changeî nephrotic syndrome in children, but should
not be used as primary therapy (3).
Ifosfamide (IF) is the other predominantly used
oxazaphosphorine agent. It is a synthetic analogue
of cyclophosphamide. IF is mostly used in combina-
tion with certain other approved antineoplastic
agents, is indicated for third line chemotherapy of
germ cell testicular cancer. Additionally, since ifos-
famideís first approval, a large variety of malignan-
cies have been studied to asses their responses.
Clinical experience shows that it is also useful for
other medical problems. Although these uses are not
included in product labelling in most countries, ifos-
famide is used in certain patients with bone cancer
(including Ewingís sarcoma), in female ovarian,
breast, cervix or endometrium cancers as well as in
head and neck, lungs cancers in both sexes.
Moreover, IF is considered to be effective in lym-
phomas, neuroblastoma, thymoma and other cancer
of the thymus and Wilmsí tumor (a cancer of the
kidneys occurring mainly in children) (4). 
It has been revealed, that cytotoxic action of all
oxazaphosphorines is closely related to the reactivi-
ty of the 2-chloroethyl substituent group, which in
turn is linked with the basicity of the central nitro-
gen atom. It was discovered that after oxazaphos-
phorines administration, these chemotherapeutics
are subject to complex biotransformation processes
before they can exert their alkylating cytotoxic prop-
erties. To sum up, the metabolic pathway consists of
three major steps; activation, toxification and deac-
tivation. The initial activation results in hydroxyla-
tion of the C-4 atom, which is effectuated by the
mixed system of liver oxidases. At a further stage of
toxification, the formed 4-hydroxyoxazaphospho-
rines get metabolized with a spontaneous elution of
acrolein and a formation of diamine derivatives of
phosphoric acid with alkylating properties.
Simultaneously, because of the fact that toxification
reaction is a rate-limiting enzymatic step, a
reversible or an irreversible deactivation may take
place. Due to the saturation of enzymes synthesizing
alkylating metabolites, reactions of dehydrogenation
(oxidation) to aldo-oxazaphosphorine forms may
occur alternatively, which formations are then fur-
ther converted into 4-keto or carboxy derivatives
that are excreted in the end. This deactivation path-
way hyperactivity may explain the presence of
oxazaphosphorine-resistant tumors (1, 5, 6).
According to Ross et al. (7), who formulated their
concept over sixty years ago, the cytotoxic action of
alkylating agents is based on the alkylation of nucle-
ophilic centres of biomolecules (such as the N7
position of guanine in DNA). Thus, the intracellular
release of alkylating agents leads to the DNA poly-
merases inhibition and specific DNA alkylation (by
the covalent bonding) with subsequent DNA poly-
merization depletion (ìsuicidal inactivationî) (1, 5,
6, 8). 
Oxazaphosphorine alkylating compounds are
still widely used cytostatic agents, however, they are
not devoid adverse reactions ñ from mild or moder-
ate disturbances to severe, even life-threating. They
have already been reported by Coggins et al. in 1960
(9). 
Both CP and IF adverse drug reactions are
multiple, including disturbances originating almost
from all systems, such as hematologic (myelosup-
pression with possible life-threatening opportunistic
infections or sepsis), gastrointestinal (moderate to
severe emesis, anorexia, and, less frequently,
abdominal discomfort, pain or diarrhea), dermato-
logic (alopecia in at least 50% of patients treated
with cyclophosphamide and 83% with ifosfamide;
typically reversible), respiratory (interstitial pul-
monary fibrosis, pneumonitis, dyspnea), endocrine
(amenorrhea associated with decreased estrogen and
increased gonadotropin in women, oligo- or
azoospermia associated with normal testosterone
and increased gonadotropin in men) and neurologi-
cal abnormalities (ototoxicity and peripheral neu-
ropathy, asthenia, dizziness, depression, or
headache) (10, 11).
Among various, possible oxazaphosphorines-
induced side effects mentioned above, genitourinary
side effects including hemorrhagic or nonhemor-
rhagic cystitis, associated with bladder overactivity
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accompanied by irritative voiding, urinary frequen-
cy, dysuria, urgency, incontinence, nocturia seem to
be one of the most important. Moreover, for ifos-
famide, renal tubular acidosis, Fanconi syndrome,
renal rickets and acute renal failure and hematuria
occurring in 6 to 92% of patients has been reported.
Ifosfamide-induced renal tubular necrosis has also
been reported as most threating side effect (12, 13).
The prevalence of HC development as a result of
CP/IF treatment was reported to be as high as about
70%. Life-threatening HC with uncontrolled hemor-
rhage is estimated at about 4% (14). 
The pathophysiological mechanism of HC
development is complex, based on oxazaphospho-
rines-derived metabolites inflammatory response
activation. 
In summary, according to Korkmaz, Topal and
Oter (14), the most likely pathomechanism of
oxazaphosphorines (more exactly: acrolein-indu-
ced) hemorrhagic cystitis, can be described using
several details. In the first step, acrolein enters into
the uroepithelium and initiates its injury by itself,
that is deepened by acrolein-evoked both ROS and
NO overproduction. Moreover, acrolein is responsi-
ble for further uroepithelial damage intensification
by some intracellular factors such as NF-κB and
AP-1 inducement. These compounds cause the over-
expression of genes encoding proinflammatory
cytokines (TNF-α and IL-1) and a further increase
in the synthesis of ROS and NO. At a later stage,
cytokines leave the uroepithelium and spread to
detrusor smooth muscle and bloodstream. It seems
that the key point in HC development plays peroxy-
nitrite synthesis that is formed from ROS and NO.
Peroxynitrite attracts cellular macromolecules
(lipids, proteins, DNA), further exaggerates bladder
damage. As a result, damage to the integrity of cells
and tissues occurs, manifesting itself in the form of
histological and morphological abnormalities, such
as swelling, bleeding and ulcerations. Thus, our cur-
rent knowledge about pathogenesis of oxazaphos-
phorines-induced hemorrhagic cystitis is evolved.
There is no doubt that this is a complex inflammato-
ry process with several cytokines, free radicals and
non-radical molecules and that all these components
of a pathophysiological description must be taken
into consideration when looking for more effective
chemopreventive compounds against CP / IF-
induced cystitis (14). The more detailed pathophys-
iological description of HC development as well as
oxazaphosphorines mechanism of action we gave in
one of our reviews (15).
Thus, the cytotoxic action oxazaphosphorine
therapy may be complicated by bladder functional
abnormalities induction resulting in bladder overac-
tivity; so called - iatrogenic overactive bladder
(OAB) syndrome. 
On a margin, the cyclophosphamide adminis-
tration to rats is regarded to be one of the oldest, but
still used experimental OAB model, described for
the first time by Cox et al. (16). 
OAB is a clinical entity, characterized due to
International Continence Society guidelines (2002
and 2006) as urgency with or without urgency
incontinence, usually with increased daytime urina-
tion frequency and nocturia (17, 18). The OAB
pathogenesis is complex, involving several neuro-
genic and myogenic disturbances, with paying the
special attention to abnormal afferent and efferent
bladder innervation, abnormal paracrine urothelium
activity and disturbed bladder smooth cells myo-
electrical activity. Thorough the description of OAB
pathophysiology is exceeding the framework of this
work, an interested reader will find more details in
other articles (19-21), including those ones of our
authorship (22).
It is worth stressing, that the idiopathic OAB is
developing at the lack of any organic disturbances
being the possible causative OAB agents, while cys-
titis accompanying oxazaphosphorines therapy
results in similar clinical manifestation. Thus, rat
oxazaphosphorines model is regarded to reflect clin-
ical idiopathic OAB. 
Aim of the study 
The aim of our study was to reveal the poten-
tial differences of autonomic nervous system activi-
ty in hemorrhagic cystitis undergoing with bladder
overactivity, evoked by two oxazaphosphorines:
cyclophosphamide (CP) and ifosfamide (IF).
Nowadays, the best non-invasive method of ANS
indirect assessment is the heart rate variability
(HRV) study. HRV is the temporary variation of R-
R intervals observed in ECG recording that is mod-
ulated by autonomic influences (23).
EXPERIMENTAL
The study protocol was approved by the First
Local Ethic Committee in KrakÛw (agreement deci-
sion 126/2010).
Animals and studied groups
The animals were obtained from the central lab-
oratory. Rats were allowed an acclimatization period
of two weeks in groups of five per cage upon their
arrival at the animal house of the Pathophysiology
Department. The animals were housed at room tem-
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perature, with 12/12 hours day-night cycle, with stan-
dard food (Labofeed, Kcynia) and ad libitum water.
During the third week, being a principal experiment
period, all animals were fed with high-energetic fod-
der to minimalize the unfavorable effects of adminis-
trated cytotoxic agents on alimentation. 
After the acclimatization period (14 days), the
animals were randomized into studied groups. We
carried out our experimental research in three essen-
tial groups: control group (group 1), cyclophos-
phamide-induced HC (CP-HC; group 2) one and
ifosfamide-induced HC (IF-HC; group 3) one. Each
group consisted of ten 10-week-old female Wistar
rats; thus the experiment employed 30 animals.
CP-HC and IF-HC model
Both cyclophosphamide and ifosfamide were
injected intraperitoneally (i.p.) to produce a model
of chemically induced hemorrhagic cystitis (HC)
with bladder overactivity. In general, depending on
CP/IF dose and route of administration, the so-
called ìacute overactive bladderî model (after high
single dose), or a chronic case (after several doses)
may be evoked (24, 25). We conducted our study on
CP-HC model caused by cyclophosphamide
(Sigma-Aldrich; 75 mg/kg body weight), adminis-
tered i.p. four times every third day during one week
(starting with the 1st day and then on the 3rd, 5th
and 7th day of a week), while IF-HC model was
induced by five time, daily administration of 50
mg/kg body weight of ifosfamide. Adjusting IF-HC
protocol to the CP-HC group, IF were administrated
in 3rd, 4th, 5th, 6th and 7th day. According to liter-
ature, this resulted in a chronic chemical bladder
inflammation (24, 25). In IF-HC group, all rats fin-
ished the study, while two animals did not survive
CP therapy, thus, in the end, we studied 8 CP-HC
rats. We also observed progressive hematuria, which
appeared in all remaining CP-HC subjects after the
last CP dose. This phenomenon occurred only in
two of animals receiving IF. On the 8th day, HRV
recording was registered in both CP and IF treated
rats and after these procedures the animals were
euthanized by pentobarbital (Morbital, Biowet,
Pu≥awy) overdose (100 mg/kg body weight).
Control group
The studied animals received saline i.p. injec-
tion from 1st till 7th day of the experiment (except
the 2nd day, because no rat received drug this day)
in similar volumes as those administrated in CP and
IF rats. HRV recordings were also performed on the
8th day of the experiment.
HRV studies
ECG recordings were performed during 20-
min rest periods under urethane anesthesia (1200
mg/kg body weight; Sigma-Aldrich) in each studied
animal. This anesthetic agent was chosen based on
literature reports suggesting a proportional (up to the
applied dose) impact on tonic activity of both the
sympathetic and parasympathetic ANS, and a rela-
tively small influence on cardiac reflexes (26, 27).
After terminating ECG registration and extrasinusal
extopics elimination, HRV analysis was performed.
Standard spectral (frequency; TP, VLF, LF, HF ñ all
in [ms◊ms] and normalized nLF and nHF in [n.u.])
parameters were calculated. The frequency range for
respective spectral components was set at: 0.18 <
VLF < 0.28 < LF < 0.78 < HF < 3; and commonly
accepted interpretation criteria were admitted.
Results were presented as the mean values ± SD.
Urinary bladder assessment
Bladders were collected in both CP-HC and IF-
HC rats, as well as in the controls, after ECG record-
ings and administration of lethal morbital dose (100
mg/kg body weight). We carefully collected blad-
ders with small proximal urethra to make a gross
visual assessment of the inflammatory changes.
Moreover, after gentle urine evacuation and blad-
ders dry on the gauze, the samples were weighted to
Table 1. Characteristics of studied rats.
Assessed Control CP-HC IF-HC Statistic ñ p value
parameters group 1 group 2 group 3 Group 1-2 Group 1-3 Group 2-3
Starting body weight 192.86 ± 4.85 189.70 ± 10.13 187.43 ± 6.8 NS NS NS
Final body weight 295.50 ± 8.21 157.0 ± 16.05 169.14 ± 8.17 0.001 0.001 NS
Bladder wet weight 0.137 ± 0.064 0.168 ± 0.06 0.137 ± 0.04 NS NS NS
Bladder wet weight / 
final body weight ratio 0.045 ± 0.023 0.108 ± 0.04 0.081 ± 0.02 0.01 0.01 NS 
NS = Not significant
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settle bladder wet weight. According to the litera-
ture, bladder wet weight is regarded to be an indirect
parameter, reflecting the cystitis and edema intensi-
fication (28-30). We also calculated bladder wet
weight to final body weight ratio to express the blad-
der weight participation independently on the rat
individual differences. The statistical analysis of
obtained results was performed, comparising control
to both studied groups as well as CP-treated (group
2) to IF-treated (group 3) animals, using parametric
Fischer-Snedecor test with α = 0.05. The final
results together with statistical estimation are given
in Table 1. 
In both studied groups (CP-HC and IF-HC),
urinary bladders were red and swollen. These histo-
logical lesions were more stressed in CP treated ani-
mals. Moreover, bladders obtained from CP-HC
group, in most cases were covered by abundant
serosal petechial suffusions. Histological inflamma-
tory changes were less pronounced in IF treated rats.
Contrary to CP-HC group, we did not reveal intra-
bladder hematomas in IF treated animals. The con-
trol rats had normal in visual inspection bladders. 
Statistical analysis 
The statistical assessment of the results
obtained in paired studied groups (CP-HC vs. con-
trol and IF-HC vs. control) was performed after
expressing them as ln values, again using parametric
Fischer-Snedecor test with α = 0.05. The expression
of the values of spectral parameters in the form of
natural logarithms was the consequence of the lack
of their normal distribution. The null (H0) hypothe-
sis of equality of analyzed parameter variations in
the two studied populations was verified versus the
alternative hypothesis (H1) of their inequality (the
presence of statistically significant differences). 
RESULTS
Animalsí weight 
The starting weight was similar in all studied
animals. At the end of the experiment (three weeks;
14 days of acclimatization and one week of oxaza-
phosphorines or vehicle administration), the final
body weight differed in individual groups. An
increase in final body weight was observed in con-
trol rats (about 53%; from 192.9 to 295.5 g), while
in two remaining groups we noticed a progressive
body weight fall, more pronounced in CP-treated
rats (mean body weight loss was about 17% - from
189.7 to 157.0 g in this group, whereas IF-treated
animals displayed smaller body weight decrease ñ
about 8%; from 184.43 to 169.14 g). The cause of
body weight loss in oxazaphosphorines treated rats
was the deterioration of their general condition
together with observed diminished food intake com-
paring to control. 
Bladder wet weight in studied groups 
The bladder wet weight did not differ signifi-
cantly in all studied groups, although this parameter
achieved the highest value in CP-HC rats. The ratio:
bladder wet weight / final body weight was the low-
est in control animals, elevated in IF-treated partici-
pants and the highest in CP-treated ones. These dif-
ferences were of statistical meaning when separate-
ly compared control to CP-HC and IF-HC groups.
This finding reflects more intensified inflammatory
changes and edemas in bladders tissue in animals
receiving CP / IF. Comparing CP-HC and IF-HC
rats, these differences were not so clear anymore,
however, in our opinion, it is worth underlying that
the general tendency suggesting the highest tissue
lesions in CP-treated rats was revealed. 
The detailed description of the results men-
tioned above is given in Table 1.
HRV time-domain parameters
Most of calculated time-domain HRV parame-
ters were similar in all studied groups, without
essential differences in control and both treated ani-
mals. Control rats were characterized by higher
range, mean NN and rMSSD comparing to those
ones treated with CP. The only difference relating to
control and IF-treated groups was also rMSSD,
which ñ contrary to the findings mentioned above ñ
was higher in IF-treated rats. 
HRV spectral-domain parameters
The spectral (frequency) HRV analysis showed
many essential differences with statistical signifi-
cance among studied groups.
In general, the values of all non-normalized
HRV spectral parameters were the highest in control
group. The clearly marked trend of the all non-nor-
malized spectral parameters fall was demonstrated
in both oxazaphosphorines treated groups. These
parameters achieved the lowest values in CP-treated
group. 
Moreover, we calculated the percentage of
individual power spectral components in total HRV
power in all analyzed groups. In control animals, the
HRV spectrum was characterized by the highest
VLF percentage, amounting almost a half of total
spectrum additionally with almost two-times higher
HF percentage comparing to LF one. In both CP and
IF treated animals, the disproportion between three
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non-normalized spectral components comparing to
their distribution in control rats was showed. We
found that the percentage of VLF markedly
increased, achieving almost three fourth of total
spectrum. Moreover, LF percentage decreased about
the half in both CP/IF treated animals, comparing to
control ones. The HF [%] also differed considerably
in both oxazaphosphorines treated participants,
amounting lower values. 
Contrary to the findings mentioned above, con-
sidering the results of normalized spectral parame-
ters we did not reveal significant differences
between control and treated rats. The nLF and nHF
values were almost the same in control and CP-
treated rats. In IF-HC group, the only essential dif-
ference was related to nLF, which was higher than in
control one (simultaneously nHF was slightly
diminished comparing to the control, although it
was not statistically significant). 
The detailed results mentioned above are given
in Table 2.
DISCUSSION
The main findings revealed in our study were:
1. Both cyclophosphamide and ifosfamide
impaired autonomic nervous system functioning.
We revealed that these oxazaphosphorines agents
diminished global autonomic activity that was more
profound after CP and this drug also produced more
intensified bladders histological lesions comparing
to IF.
2. Moreover, CP treatment was associated with
changes of non-normalized HRV spectral compo-
nents percentage distribution - a marked VLF [%]
increase together with LF [%] and HF [%] decrease
were observed. Taking into consideration the next
findings, demonstrating the lack of both normalized
nLF and nHF values, the VLF percentage change
seems to be of special meaning. In our opinion,
autonomic impairment after CP was manifested by
decrease of total autonomic tension with relative
VLF functional predominance, due to systemic
Table 2. Time- and spectral domain HRV analysis after 4-times cyclophosphamide (CP; 75 mg/kg body weight) and 5-times ifosfamide
(IF; 50 mg/kg body weight) administration in rats.
HRV parameters Control CP-HC IF-HC STATISTICAL p value
Group 1 Group 2 Group 3        (for ln HRV parameters values)
Time-domain HRV parameters Group 1-2 Group 1-3
max NN [ms] 188.8 ± 0.28 185.4 ± 7.0 188.6 ± 0.8 NS NS
min NN [ms] 139.3 ± 0.37 145.1 ± 9.5 141.8 ± 5.6 NS NS
range [ms] 49.5 ± 0.5 40.2 ± 16.1 46.8 ± 5.4 0.001 NS
mean NN [ms] 163.4 ± 10.3 157.9 ± 12.4 164.4 ± 9.4 0.05 NS
average HR [1/min] 368.3 ± 22.6 381.9 ± 29.1 365.9 ± 20.9 NS NS
SDNN 8.7 ± 2.7 6.6 ± 3.2 12.7 ± 5.0 NS NS
rMSSD 13.0 ± 7.3 5.5 ± 5.2 19.3 ± 15.2 0.05 0.02
Spectral-domain HRV parameters
TP [ms2] 36.1 ± 17.8 10.6 ± 15.6 28.7 ± 36.9 0.04 0.01
VLF [ms2] 19.2 ± 15.7 7.0 ± 9.2 15.9 ± 20.8 0.02 NS
LF [ms2] 5.4 ± 2.5 1.4 ± 2.5 3.8 ± 7.2 0.05 0.04
HF [ms2] 11.5 ± 8.9 2.2 ± 4.0 9.1 ± 13.7 0.001 0.04
LF/HF 0.7 ± 0.6 0.6 ± 0.6 1.1 ± 0.7 NS 0.003
nLF [n.u.] 36.6 ± 16.0 33.6 ± 21.6 45.2 ± 21.1 NS 0.001
nHF [n.u.] 63.4 ± 16.0 66.4 ± 21.6 54.8 ± 21.1 NS NS
VLF [%] 47.1 ± 26.6 76.2 ± 13.8 71.6 ± 28.2 0.009 0.009
LF [%] 16.4 ± 5.5 8.6 ± 6.3 8.3 ± 5.4 0.001 0.001
HF [%] 36.5 ± 21.5 15.2 ± 9.1 20.2 ± 27.6 0.05 0.01
NS = Not significant
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(including cardiovascular) stress followed by cyto-
toxic CP action.
3. IF produced smaller autonomic distur-
bances, and gentler bladders histological abnormali-
ties comparing to CP. However, similar to CP, VLF
[%] relative augmentation together with LF [%] and
HF [%] drop accompanied the global ANS activity
decrease. Additionally, in the case of IF treatment, a
slight trend of nLF increase with nHF decrease was
noted, suggesting the possible functional rearrange-
ment between sympathetic (nLF) and parasympa-
thetic (nHF) tension. 
During normal sinus rhythm, the heart rate
varies from beat to beat. Heart rate variability results
from the dynamic interplay between multiple mech-
anisms that regulate the instantaneous heart rate
(31). Among them, autonomic nervous system is the
most prominent factor determining cardiac func-
tions and its rate, thus the heart rate variability
study, reflecting ANS impact on heart rate is nowa-
days considered to be a good tool for ANS activity
assessment. As it was mentioned in the introduction,
the basic data for the HRV calculation is the
sequence of time intervals between normal heart
beats. The heart is innervated by both parasympa-
thetic fibers, that cause the interbeat interval
becomes longer and the sympathetic ones, causing
the time between heart beats to become shorter. The
fluctuations between normal beats, expressed by
main HRV parameter ñ mean NN [ms] and some
derived statistical parameters are the time-domain
HRV analysis (31, 32). Moreover, additional insight
into the nature of heart rate fluctuations may be
gained by analyzing the fluctuations in the frequen-
cy domain analysis, based on the fast Fourier trans-
formation method. The frequency ñ spectral HRV
analysis provides information of how power (vari-
ability) distributes as a function of frequency as well
as yields clinical interpretation of obtained results.
Many physiological studies showed that the
parasympathetic influences are pervasive at the fre-
quency range 0.15ñ0.4 Hz ( > 6 s cycle length) of
the heart rate power spectrum, whereas the sympa-
thetic influences switch at about 0.04ñ0.15Hz (2.5
to 6.0 s cycle length). The most important premises
enabling to set HF component as a marker of
parasympathetic activity were the findings that res-
piratory related heart rate variation occurs at a high
frequency (typically around 0.25 Hz) and can be
abolished by vagal blockade. On the other hand,
cyclical variation occurring in association with
changes in baroreceptors activity is noted at a fre-
quency of about 0.10 Hz that was also correlated
with direct measures of sympathetic nerves activity.
These premises suggested sympathetic-mediated LF
origin. However, vagal blockade or excitation also
produced some modification of LF component
power. Therefore, a common agreement exists that
high frequency (HF) band represents parasympa-
thetic influences while low one (LF) has a mixed ñ
sympathetic and parasympathetic character. There is
also a possibility to express pure sympathetic or
parasympathetic activity by normalized nLF or nHF;
respectively, as the reference of LF or HF powers to
total HRV power with the another spectral compo-
nent ñ VLF omission (23, 33, 34). The short-term
HRV spectrum also contains very low frequencies ñ
VLF (0.0033ñ0.04 Hz; > 25 s cycle length), howev-
er, it is not possible to elucidate whether more
heightened sympathetic or parasympathetic activity
contributes to VLF power, due to still unknown
physiological background of this HRV component
development. VLF is regarded as reflecting circadi-
an and neuroendocrine rhythms, thermoregulatory
processes, renin-angiotensin system activity, and
hemodynamic feedback delays. Although, the
meaning of VLF is still not clearly understood, most
HRV authorities recommend considering this com-
ponent as a marker of sympathetic activity, also
reflecting general systemic stress (23). However, on
the other hand, there are also different opinions,
regarding VLF as the marker of parasympathetic
stimulation. According to Taylor et al. (35), VLF
depends primarily on the presence of parasympa-
thetic outflow. These authors showed that atropine
almost completely abolished VLF power and other
spectral components, suggesting that also HRV
present in the VLF band is driven by parasympa-
thetic modulation. Silva Soares et al. (36) demon-
strated in experimental study that stimulation with
pyridostigmine (reversible cholinesterase inhibitor)
produced a strong increase in VLF. Therefore, the
prognostic value of VLF oscillations may also
derive from the fundamental importance of
parasympathetic mechanisms. 
Bringing back our results to introduced inter-
pretative HRV assumptions above, we can ascertain
that oxazaphosphorines-induced cystitis is charac-
terized by global decrease of autonomic tension,
affecting both sympathetic and parasympathetic
branch. We revealed TP decrease, as well as LF, HF
and VLF drop, suggesting both sympathetic and
parasympathetic withdrawal. On the other hand,
however, the normalized nLF and nHF values were
the same in control and CP/IF treated rats (except
nLF in IF-HC animals that was higher). Thus, in our
opinion, in the light of these settlements stated
above, the relative percentage changes of main spec-
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tral components pay the special attention, especially
those relating to VLF [%]. We revealed in both CP-
HC and IF-HC groups the considerable proportional
part increase of VLF in HRV spectrum. Taking
under the attention the VLF interpretation criteria,
this finding may be treated, however, as a reflection
of enlarged sympathetic activity due to inflammato-
ry changes and blood proinflammatory cytokines
occurrence. It also seems to be interesting to con-
front our HRV results with the cholinergic-antiin-
flammatory pathway theory. This physiological phe-
nomenon is associated with the nervous modulation
of pro-inflammatory cytokines release from the
immune-competitive cells. An excessive expression
of such kind of proteins contributes to the larger tis-
sue inflammatory damage. The anti-inflammatory,
compensatory mechanism exists that is based on the
vagal nerve activation. It has already been demon-
strated that stimulation of vagal nerve significantly
inhibits one of the most powerful proinflammatory
cytokine ñ tumor necrosis factor (TNF-α) release
(37). The mechanism of this vagal inhibition
involves acetylocholine ñ a neurotransmitter of the
vagal fibers and the nicotinic acetylocholine recep-
tor expressed on cytokine-producing macrophages.
The administration of acetylocholine to the α7 sub-
unit of the nicotinic receptor with subsequent intra-
cellular signal transduction through the affecting of
nuclear factor ñ κB, results in a reduced TNF-α pro-
duction, together with other pro-inflammatory
agents: interleukin 1 and 6 (38, 39). 
There is a relationship between heart rate vari-
ability and inflammatory markers. The majority of
studies reported that parasympathetic tone is
inversely related to inflammatory markers (38). Low
HF (reflecting pure parasympathetic tone) and LF ñ
a spectral component reflecting both sympathetic
and parasympathetic tension, are often associated
measure linked to inflammatory intensification. It
can be explained based on the cholinergic antiin-
flammatory arc theory mentioned above ñ decreased
vagus nerve activity and associated loss of the tonic
inhibitory influence of cholinergic antiinflammatory
action on immune cells response, may significantly
enhance proinflammatory cytokine release (39). We
revealed similar trend in our study ñ in both CP/IF
treated rats, both HF and LF were lower than in con-
trol, thus suggesting possible disturbed cholinergic
antiinflammatory pathway. Taking again into con-
sideration our next findings demonstrating no differ-
ences between normalized nLF and nHF values and,
on the other hand, the relative increase of VLF per-
centage part in total HRV spectrum, it seems, that
this parameter may reflect diminished parasympa-
thetic activity and relative sympathetic predomi-
nance. 
CONCLUSION
According to us, it seems possible that the
vagal withdrawal and ñ as a consequence ñ sympa-
thetic overactivity, reflected by VLF [%] enlarge-
ment and HF and LF [%] diminishing (as well as
LF and HF values decrease), may be an evidence of
impaired anti-inflammatory cholinergic pathway,
aggravating bladder inflammatory lesions. These
findings support the clinical evidence indicating
that when vagus nerve activity is deficient, inflam-
mation is excessive (39). This is also consistent
with other reports, demonstrating altered HRV in
the presence of systemic infection, correlated with
its severity (40). It also seems rational that the
activity of parasympathetic branch, being a part of
whole autonomic tension estimation, should be
performed in each patient receiving oxazaphospho-
rines cytotoxic therapy. Thus, similar to hemoglo-
bin HbA1C level assessment in diabetes (as a fac-
tor reflecting glycemic control), the heart rate vari-
ability study could be developed to monitor the
functional autonomic state during oxazaphospho-
rines treatment to detect patients subpopulation
with the low vagal activity, being particularly
threatened with the development of clinically more
intensified HC. 
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